EP1366190A2 - Procede pour quantifier des methylations par cytosine dans de l'adn genomique amplifie de maniere complexe - Google Patents
Procede pour quantifier des methylations par cytosine dans de l'adn genomique amplifie de maniere complexeInfo
- Publication number
- EP1366190A2 EP1366190A2 EP01989384A EP01989384A EP1366190A2 EP 1366190 A2 EP1366190 A2 EP 1366190A2 EP 01989384 A EP01989384 A EP 01989384A EP 01989384 A EP01989384 A EP 01989384A EP 1366190 A2 EP1366190 A2 EP 1366190A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- sample
- adapters
- amplified
- genomic dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000030933 DNA methylation on cytosine Effects 0.000 title claims abstract description 9
- 230000003321 amplification Effects 0.000 claims abstract description 26
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 26
- 239000012925 reference material Substances 0.000 claims abstract description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 35
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 32
- 238000003752 polymerase chain reaction Methods 0.000 claims description 30
- 108091034117 Oligonucleotide Proteins 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 25
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 22
- 230000011987 methylation Effects 0.000 claims description 21
- 238000007069 methylation reaction Methods 0.000 claims description 21
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 15
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 14
- 229940104302 cytosine Drugs 0.000 claims description 12
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 229940035893 uracil Drugs 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006326 desulfonation Effects 0.000 description 2
- 238000005869 desulfonation reaction Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
Definitions
- the invention relates to a method for the quantification of cytosine methylations of a genomic DNA sample with an unknown methylation status by comparison with a demethylated reference DNA.
- 5-Methylcytosine is the most common covalently modified base in the DNA of eukaryotic cells. For example, it plays a role in the regulation of transcription, genomic imprinting and in tumorigenesis. The identification of 5-methylcytosine as a component of genetic information is therefore of considerable interest. However, 5-methylcytosine positions cannot be identified by sequencing since 5-methylcytosine has the same base pairing behavior as cytosine. In addition, in the case of PCR amplification, the epigenetic information which the 5-methylcytosines carry is completely lost.
- a chemical reaction or enzymatic treatment of the genomic DNA is usually carried out, as a result of which the cytosine can be distinguished from the methylcytosine bases.
- a common method is the implementation of genomic DNA with bisulfite, which is alkaline
- Demethylated DNA is used in the prior art in numerous methods for quantifying DNA methylation. Representative are: “Rapid quantification of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension” (Gonzalgo, ML, Jones PA Nucleic Acids Res. 25, 2529 (1997)) and “Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA “(Warnecke, PM, Stirzaker, C, Melki, JR, Douglas, SM, Paul, CL, Clark, SJ 25, 4422 (1997)).
- This demethylated DNA is e.g. obtained from cells that are demethylated in the target sequence or from cells that lack the enzyme DNA methyltransferase.
- this method is not suitable for carrying out complex amplifications which are intended to provide many fragments at the same time for the methylation detection.
- this is essential since the sample to be examined, for the methylation analysis of which the reference DNA is produced, is usually only amplified after the bisulfite treatment. In the case of a complex PCR reaction, the comparability of reference and sample is no longer possible, since they contain potentially different fragments.
- the present invention provides a method for the analysis of cytosine methylations in genomic DNA samples, for which purpose DNA with a degree of methylation of 0% is produced as reference material. This is the first time possible to provide an essentially unmethylated reference DNA for complex amplifications.
- the present invention describes a method for providing demethylated DNA as reference material for the analysis of cytosine methylations in genomic DNA samples using complex amplifications.
- the following process steps are carried out in detail:
- a genomic DNA sample is amplified with primers which are either very short or degenerate oligonucleotides or oligonucleotides complementary to adapters.
- primers which are either very short or degenerate oligonucleotides or oligonucleotides complementary to adapters.
- a restriction enzyme is cut before amplification and the adapters, which are short nucleotide fragments of known sequence, are ligated to the ends of the resulting DNA fragments.
- the amplificates are treated chemically in such a way that at the 5-position unmethylated cytosine bases are converted into uracil, thymine or into another base which is unlike the cytosine in hybridization behavior, while the 5-methylcytosine bases remain essentially unchanged. This is understood below as chemical pretreatment.
- the chemically pretreated amplificates are in turn amplified. Either several specifically hybridizing oligonucleotides or oligonucleotides complementary to the adapters are used as primers. In the latter case, chemical pretreatment is also carried out.
- a genomic DNA sample to be examined is cut using a restriction enzyme. Adapters are ligated to the ends of the DNA fragments and the sample is subsequently divided. The first part of the sample is amplified with primer oligonucleotides that are complementary to the adapters. However, the second part of the sample is not amplified.
- the two parts of the sample are chemically pretreated and amplified separately, using primer oligonucleotides complementary to the adapters.
- the two parts of the sample are then analyzed.
- the first part of the sample provides the reference value for a degree of methylation of 0%.
- the second part of the sample provides the measured value which essentially corresponds to the degree of methylation in the original genomic DNA sample.
- the genomic DNA to be analyzed is preferably obtained from the usual sources for DNA, such as. B. cell lines, blood, sputum, stool, urine, brain spinal fluid, paraffin-embedded tissue, for example tissue from the eyes, intestine, kidney, brain, heart, prostate, lungs, chest, liver, skin or bone marrow, histological slides and all possible combinations of them.
- the polymerase chain reaction (PCR) is used for the amplification.
- PCR polymerase chain reaction
- a heat-resistant DNA polymerase is used for the polymerase chain reaction.
- the amplification of several identical or several different DNA sections is preferably carried out in a reaction vessel.
- restriction endonucleases The following are preferably used as restriction endonucleases: Rsal, Dpnl, Dpnll, Msel, Sau3AI, Alul, NIalll, Hael- II, Bfal, Tsp509I, BstUI or Mbol.
- the amplificates are separated from the reagents and other constituents of the reaction mixture by binding to a solid phase or to a gel and washing steps.
- the reagents and the other constituents of the reaction mixture are preferably diluted in such a way that they are no longer a hindrance in the subsequent amplification, but the concentration of the amplified treated is still sufficient for the second amplification.
- the demethylated reference DNA produced is particularly preferably analyzed in the same way as a sample DNA to be examined. In the analysis, this reference DNA provides the comparison value for a degree of methylation of 0%.
- an enzymatically methylated DNA which was treated in the following in the same way as the sample DNA, is preferably used as a reference for a degree of methylation of 100%.
- Example la Preparation of a demethylated reference DNA by means of multiplex PCR
- the following example relates to the preparation of a downmethylated DNA sample that serves as a reference in comparison to an unknown methylated DNA.
- you uses a genomic DNA sample, which in this case was digested with the restriction enzyme, Mssl.
- (1-40 ng) of the cut DNA are multiplied by a pre-amplification by a DOP-PCR (degenerate oligonucleotide primed polymerase chain reaction) according to the Nelson method (VG Cheung, SF Nelson, PNAS 93, 1476-1479, 1996) with the genomic primer oligonucleotide 5 '-CCGACTCGAGNNNNNNATGTG G-3'.
- the method is primarily used to pre-amplify very small amounts of genomic DNA in order to allow multiple genetic analysis from 2-15 ⁇ g (200-1000 bp). In the amplification, all methyl cytosines are treated as cytosine bases.
- the PCR reaction is carried out in the Master Cycler Gradient (Eppendorf, Hamburg) with the following program.
- the bisulfite reaction leads to the conversion of all cytosine bases into uracil.
- To purify the bisulfited DNA it is bound to a reversed phase C18 solid phase and freed of chemicals by washing with a suitable buffer solution. Then the DNA with a polar solvent such as. B.
- the specific amplification is carried out with 128 primer oligonucleotides, at least 64 primer oligonucleotides being labeled with Cy5 (Amersham Pharmacia). This is a primer oligonucleotide from a pair of primers.
- primer oligonucleotide mixture (128 primer oligonucleotides, 64 of which are labeled Cy5, 0.78 pmol / ul of each)
- the PCR reaction is carried out in the Master Cycler Gradient (Eppendorf, Hamburg) with the following program. 15 min 95 ° C
- the generated PCR certificates were analyzed by agarose gel electrophoresis (1.5% agarose in 0.5 ⁇ TBE buffer, Sambrook et al.). For this, 4 ⁇ l of the PCR approach are subjected to gel electrophoresis. Under the specified conditions, 64 genes are successfully amplified simultaneously.
- Example Ib Preparation of an unknown methylated DNA sample by means of multiplex PCR
- example Ib relates to the preparation of an unknown methylated DNA sample, which is compared with the downmethylated reference DNA from example la.
- a genomic DNA sample is used, which in this case was cleaved with the restriction enzyme Mssl.
- the sample is then reacted with hydrogen sulfite (bisulfite, disulfite).
- the first method (Olek et al., Nucl. Acids. Res. 1996, 24, 5064-5066) is a reaction with hydrogen sulfite and a radical scavenger, the DNA being embedded in agarose. The desulfonation of the DNA also takes place in agarose.
- An organic reagent that supports denaturation is added and the mixture is incubated at elevated temperature.
- hydrogen sulfite all cytosine bases are converted to uracil in both methods, methyl cytosines being retained.
- a polar solvent such as. B.
- the preamplification of the hydrogen sulfite-treated DNA is carried out using degenerate primer oligonucleotides (5 '-TTATAATGTTTT and 5' -TATATACTAAT).
- the subsequent amplification with Cy5-labeled bisulfite-specific primer oligonucleotides is carried out with the 128 primer oligonucleotides described in Example 1a, the same primer oligonucleotide being Cy5-labeled.
- the amplificates are also subjected to agarose gel electrophoresis for analysis.
- Example lc Comparison of the unknown methylated DNA sample with the downmethylated reference DNA
- the comparison of the unknown methylated DNA sample with the downmethylated reference DNA is preferably carried out by hybridization to an oligonucleotide array. Fluorescent dots are visible according to the position on the array. It is noticeable that certain points on the array are relative to the others and to the reference DNA shows a significantly increased or decreased fluorescence, provided the amplified products are present in a comparable concentration in the individual samples to be examined. The intensities of the fluorescent dye Cy5 (635 nm) in the individual amplificates are measured. The manner in which fluorescence measurements are evaluated is known to the person skilled in the art.
- a genomic sequence is enzymatically cleaved by adding a restriction enzyme, here Nallall (Fermentas), which recognizes the sequence CATG. Fragments with an average size of 400 bp are generated. The cleaved fragments have 3 'overhanging CATG ends and are ligated to the sequence sections with the oligomer with the genomic sequence TGTCATCCTGTTGTCATG with addition of T4-DNA ligase according to standard conditions (fermentas) and non-ligated adapters according to standard conditions with a cleaning kit (Qiaquick PCR Purification Kit, Qiagen) removed.
- a restriction enzyme here Nallall (Fermentas)
- Fragments with an average size of 400 bp are generated.
- the cleaved fragments have 3 'overhanging CATG ends and are ligated to the sequence sections with the oligomer with the genomic sequence TGTCATCCTGTTGTCATG with addition of T4-DNA ligase according to standard
- the single-stranded ends are then supplemented to form the double-strand with Klenow enzyme (DNA polymerase I, Röche Molecular Biochemicals) and dNTPs (FIG. La).
- Klenow enzyme DNA polymerase I, Röche Molecular Biochemicals
- dNTPs FIG. La
- a reference DNA proceed as follows: In the following step, the ligated sequence sections are amplified in a PCR reaction with the addition of primer oligonucleotides with the sequence TGTCATCCTGTTGTCATG and with a heat-resistant DNA polymerase. The PCR reaction is carried out in
- the DNA is treated using bisulfite (hydrogen sulfite, disulfite) in such a way that all of the cytosines that are not methylated at the 5-position of the base are changed in such a way that a base which is different with regard to the base pairing behavior is formed, while the base in 5-position methylated cytosines remain unchanged.
- bisulfite hydrogen sulfite, disulfite
- the treated DNA sample is diluted with water or an aqueous solution. Desulfonation of the DNA (20 min, 96 ° C.) at pH 9 is then preferably carried out.
- the DNA sample is amplified with the primers now complementary to the bisulfite-treated DNA, again in a polymerase chain reaction.
- the PCR reaction is carried out in the master cycler gradient (Eppendorf, Hamburg) with the following parameters: Denaturation: 15 minutes (min) at 96 ° C, the following cycles are repeated 45 times: 60 seconds (sec) at 96 ° C , 45 sec at 42 ° C, 60 sec at 72 ° C and subsequent incubation for 10 minutes at 72 ° C (Fig. Ib).
- the cut DNA ligated with adapters (FIG. 1 a) must be treated with bisulfite.
- a PCR is carried out, the primer oligonucleotides with the sequences TGTTATTTTGTT-GTTTAG and TATCATCCTATTATGATA being used.
- the PCR reaction is carried out in the master cycler gradient (Eppendorf, Hamburg) with the following parameters: Denaturation: 15 minutes (min) at 96 ° C, the following cycles are repeated 45 times: 60 seconds (sec) at 96 ° C, 45 sec at 42 ° C, 60 sec at 72 ° C and subsequent incubation for 10 minutes at 72 ° C.
- the detection of the hybridization product is based on Cy5 fluorescence-labeled primer oligonucleotides which were used for the amplification.
- a hybridization reaction of the amplified DNA with the oligonucleotide only occurs if there is a methylated cytosine in the bisulfite-treated DNA at this point. The methylation status of the respective cytosine to be examined thus decides on the hybridization product.
- Figure la Restriction enzyme, Nlalll b. Adapter 1 5 '-TGTCATCCTGTTGT, ligase e.g. T4 DNA c. Klenow enzyme (DNA polymerase I), dNTP's, buffer d. Cleaning (Qiaquick cleaning kit)
- Figure Ib e. PCR, primer 5 '-TGTCATCCTGTTGTCATG, dNTP's, buffer, TAQ f. Reaction with hydrogen sulfite g. PCR, primer 1 5 '-TGTTATTTTGTTGTTATG, primer 2 5'- TATCATCCTATTATCATA
- Figure 2a Reaction with hydrogen sulfite b. PCR, primer 1 5 '-TGTTATTTTGTTGTTATG, primer 2 5'- TATCATCCTATTATCATA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé de préparation d'ADN déméthylé utilisé comme matière de référence pour l'analyse de méthylations par cytosine dans des échantillons d'ADN génomiques par utilisation d'amplifications complexes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10061348A DE10061348C2 (de) | 2000-12-06 | 2000-12-06 | Verfahren zur Quantifizierung von Cytosin-Methylierungen in komplex amplifizierter genomischer DNA |
DE10061348 | 2000-12-06 | ||
PCT/DE2001/004617 WO2002046452A2 (fr) | 2000-12-06 | 2001-12-05 | Procede pour quantifier des methylations par cytosine dans de l'adn genomique amplifie de maniere complexe |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1366190A2 true EP1366190A2 (fr) | 2003-12-03 |
Family
ID=7666462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01989384A Withdrawn EP1366190A2 (fr) | 2000-12-06 | 2001-12-05 | Procede pour quantifier des methylations par cytosine dans de l'adn genomique amplifie de maniere complexe |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050019762A1 (fr) |
EP (1) | EP1366190A2 (fr) |
AU (1) | AU2002227866A1 (fr) |
DE (1) | DE10061348C2 (fr) |
WO (1) | WO2002046452A2 (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1774511B (zh) * | 2002-11-27 | 2013-08-21 | 斯昆诺有限公司 | 用于序列变异检测和发现的基于断裂的方法和系统 |
AU2003900368A0 (en) * | 2003-01-24 | 2003-02-13 | Human Genetic Signatures Pty Ltd | Assay for nucleic acid molecules |
US20060024676A1 (en) * | 2003-04-14 | 2006-02-02 | Karen Uhlmann | Method of detecting epigenetic biomarkers by quantitative methyISNP analysis |
AU2004235331B2 (en) * | 2003-04-25 | 2008-12-18 | Sequenom, Inc. | Fragmentation-based methods and systems for De Novo sequencing |
US7288373B2 (en) * | 2003-05-02 | 2007-10-30 | Human Genetic Signatures Pty Ltd. | Treatment of methylated nucleic acid |
ATE476523T1 (de) | 2003-06-17 | 2010-08-15 | Human Genetic Signatures Pty | Verfahren zur genomamplifikation |
DE602004018801D1 (de) | 2003-09-04 | 2009-02-12 | Human Genetic Signatures Pty | Nukleinsäurenachweistest |
US9394565B2 (en) * | 2003-09-05 | 2016-07-19 | Agena Bioscience, Inc. | Allele-specific sequence variation analysis |
US9249456B2 (en) | 2004-03-26 | 2016-02-02 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
US7608394B2 (en) * | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
US20060019270A1 (en) * | 2004-04-01 | 2006-01-26 | Board Of Regents The University Of Texas System | Global DNA methylation assessment using bisulfite PCR |
US8168777B2 (en) | 2004-04-29 | 2012-05-01 | Human Genetic Signatures Pty. Ltd. | Bisulphite reagent treatment of nucleic acid |
AU2005284980A1 (en) * | 2004-09-10 | 2006-03-23 | Sequenom, Inc. | Methods for long-range sequence analysis of nucleic acids |
EP1794173B1 (fr) * | 2004-09-10 | 2010-08-04 | Human Genetic Signatures PTY Ltd | Bloqueur d'amplification comprenant des acides nucleiques intercalants (ina) contenant des pseudonucleotides intercalants (ipn) |
ES2399054T3 (es) | 2004-12-03 | 2013-03-25 | Human Genetic Signatures Pty Ltd | Métodos para simplificar ácidos nucleicos microbianos mediante modificación química de citosinas |
AU2005318874B2 (en) * | 2004-12-23 | 2007-05-03 | Human Genetic Signatures Pty Ltd | Detection of human papilloma virus |
US7449297B2 (en) | 2005-04-14 | 2008-11-11 | Euclid Diagnostics Llc | Methods of copying the methylation pattern of DNA during isothermal amplification and microarrays |
EP1883707B1 (fr) | 2005-05-26 | 2014-04-09 | Human Genetic Signatures PTY Ltd | Amplification par deplacement de brin isotherme utilisant des amorces contenant une base non reguliere |
ATE531820T1 (de) | 2005-09-14 | 2011-11-15 | Human Genetic Signatures Pty | Gesundheitszustandstest |
US20070122818A1 (en) * | 2005-10-31 | 2007-05-31 | Abhijit Mazumder | Gene methylation assay controls |
US20080050738A1 (en) * | 2006-05-31 | 2008-02-28 | Human Genetic Signatures Pty Ltd. | Detection of target nucleic acid |
JP2008136404A (ja) * | 2006-11-30 | 2008-06-19 | Sysmex Corp | Dnaメチル化検出における非メチル化シトシン変換処理後のdna量の確認方法 |
WO2008091913A2 (fr) * | 2007-01-23 | 2008-07-31 | Sequenom, Inc. | Procédé d'évaluation précise d'une qualité d'adn après traitement au bisulfite |
US20080213870A1 (en) * | 2007-03-01 | 2008-09-04 | Sean Wuxiong Cao | Methods for obtaining modified DNA from a biological specimen |
EP2126120A4 (fr) * | 2007-03-16 | 2011-03-30 | Human Genetic Signatures Pty | Dosage de l'expression génétique |
US8685675B2 (en) * | 2007-11-27 | 2014-04-01 | Human Genetic Signatures Pty. Ltd. | Enzymes for amplification and copying bisulphite modified nucleic acids |
CA2709632A1 (fr) * | 2007-12-20 | 2009-07-02 | Human Genetic Signatures Pty Ltd | Elimination des contaminants associes a l'amplification des acides nucleiques |
US8709726B2 (en) * | 2008-03-11 | 2014-04-29 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
US8962247B2 (en) * | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
US8476013B2 (en) * | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
WO2010048337A2 (fr) * | 2008-10-22 | 2010-04-29 | Illumina, Inc. | Préservation d'informations liées à une méthylation d'adn génomique |
US9926593B2 (en) | 2009-12-22 | 2018-03-27 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
CN102533944B (zh) * | 2010-12-10 | 2014-04-09 | 深圳华大基因科技服务有限公司 | 用于甲基化dna的富集和测序的半甲基化接头及其用途 |
US8450061B2 (en) | 2011-04-29 | 2013-05-28 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
KR101912488B1 (ko) | 2011-09-07 | 2018-10-26 | 휴먼 제네틱 시그너처스 피티와이 엘티디 | 분자 검출 분석법 |
EP3401399B1 (fr) | 2012-03-02 | 2020-04-22 | Sequenom, Inc. | Méthodes et procédés d'évaluation non invasive de variations génétiques |
US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP2872648B1 (fr) | 2012-07-13 | 2019-09-04 | Sequenom, Inc. | Procédés et compositions pour l'enrichissement basé sur la méthylation d'un échantillon maternel en acide nucléique foetal, utiles pour les diagnostics prénatals non invasifs |
US11060145B2 (en) | 2013-03-13 | 2021-07-13 | Sequenom, Inc. | Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus |
EP3117011B1 (fr) | 2014-03-13 | 2020-05-06 | Sequenom, Inc. | Méthodes et procédés d'évaluation non invasive de variations génétiques |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19754482A1 (de) * | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
DE19853398C1 (de) * | 1998-11-19 | 2000-03-16 | Epigenomics Gmbh | Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischer DNA |
DE19905082C1 (de) * | 1999-01-29 | 2000-05-18 | Epigenomics Gmbh | Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischen DNA-Proben |
DE19935772C2 (de) * | 1999-07-26 | 2002-11-07 | Epigenomics Ag | Verfahren zur relativen Quantifizierung der Methylierung von Cytosin Basen in DNA-Proben |
IL154663A0 (en) * | 2000-09-01 | 2003-09-17 | Epigenomics Ag | Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3' |
DE10050942B4 (de) * | 2000-10-10 | 2005-11-17 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen |
-
2000
- 2000-12-06 DE DE10061348A patent/DE10061348C2/de not_active Expired - Fee Related
-
2001
- 2001-12-05 US US10/433,742 patent/US20050019762A1/en not_active Abandoned
- 2001-12-05 WO PCT/DE2001/004617 patent/WO2002046452A2/fr not_active Application Discontinuation
- 2001-12-05 EP EP01989384A patent/EP1366190A2/fr not_active Withdrawn
- 2001-12-05 AU AU2002227866A patent/AU2002227866A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0246452A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002227866A1 (en) | 2002-06-18 |
DE10061348A1 (de) | 2002-06-20 |
US20050019762A1 (en) | 2005-01-27 |
WO2002046452A3 (fr) | 2003-09-18 |
DE10061348C2 (de) | 2002-10-24 |
WO2002046452A2 (fr) | 2002-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10061348C2 (de) | Verfahren zur Quantifizierung von Cytosin-Methylierungen in komplex amplifizierter genomischer DNA | |
EP1423533B1 (fr) | Procede tres sensible pour detecter la methylation de la cytosine | |
DE69804143T2 (de) | Verfahren zur charakterisierung von nukleinsäuremolekulen, das die erzeugung von verlängerbaren aufwärtsgelegenen dns-fragmenten, die durch spaltung der nukleinsäure an einer abasischen stelle entsteht, umfasst | |
DE69527444T2 (de) | Glycosylase verwendende detektion von bestimmten nukleinsäuresequenzen | |
DE60029323T3 (de) | Verfahren zur analyse der dna-methylierung mit hoher durchsatzrate | |
DE10112515B4 (de) | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität | |
DE60305150T2 (de) | Quantitativer nachweis der methylierung in dna proben | |
DE69531542T2 (de) | Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse | |
DE10056802B4 (de) | Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik | |
DE10201138A1 (de) | Verfahren zum Nachweis von Cytosin-Methylierungsmustern durch exponentielle Ligation hybridisierter Sondenoligonukleotide | |
DE69121791T2 (de) | Verfahren zur quantitativen Bestimmung von DNS-Sequenzen | |
EP1369493B1 (fr) | Procédé pour la détermination quantitative du degré de methylation de cytosines en positions CpG | |
DE10236406C1 (de) | Verfahren zur Amplifikation von Nukleinsäuren mit geringer Komplexität | |
EP1853724B1 (fr) | Procédé d'analyse des méthylations de la cytosine dans l'adn | |
EP1228246B1 (fr) | Procede permettant de distinguer les modifications de methylation en position 5 | |
WO2007009822A2 (fr) | Procede pour la quantification d'adn methyle | |
DE10392538B4 (de) | Verfahren zur Analyse von methylierten Nukleinsäuren | |
DE10132211A1 (de) | Nachweis spezifischer Dinukleotide in DNA-Proben durch Fluoreszenzresonanzenergietransfer (FRET) | |
EP1711628B1 (fr) | Procede pour calibrer et controler des methodes d'analyse de methylation au moyen d'adn non methyle | |
DE10160983A1 (de) | Verfahren und Integrierte Vorrichtung zum Nachweis von Cytosinmethylierungen | |
DE102004002257B4 (de) | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA mit Hilfe von DNA-Reparaturenzymen | |
EP1735460A1 (fr) | Procede d'analyse pour determiner la methylation de la cytoseine | |
DE10044543A1 (de) | Verfahren zur Bestimmung des Methylierungsgrades von bestimmten Cytosinen in genomischer DNA im Sequenzkontext 5'-CpG-3' |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030530 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EPIGENOMICS AG |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070703 |